JP6600637B2 - 膵臓がんを決定するための方法、アレイおよびそれらの使用 - Google Patents

膵臓がんを決定するための方法、アレイおよびそれらの使用 Download PDF

Info

Publication number
JP6600637B2
JP6600637B2 JP2016552704A JP2016552704A JP6600637B2 JP 6600637 B2 JP6600637 B2 JP 6600637B2 JP 2016552704 A JP2016552704 A JP 2016552704A JP 2016552704 A JP2016552704 A JP 2016552704A JP 6600637 B2 JP6600637 B2 JP 6600637B2
Authority
JP
Japan
Prior art keywords
expression
measuring
alternative
additional embodiment
pancreatic cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016552704A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016537652A5 (enExample
JP2016537652A (ja
Inventor
カール・アーネ・クリステル・ボーレバエック
クリステル・ラーシュ・ベルティル・ウィングレン
Original Assignee
イムノヴィア・アクチエボラーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イムノヴィア・アクチエボラーグ filed Critical イムノヴィア・アクチエボラーグ
Publication of JP2016537652A publication Critical patent/JP2016537652A/ja
Publication of JP2016537652A5 publication Critical patent/JP2016537652A5/ja
Application granted granted Critical
Publication of JP6600637B2 publication Critical patent/JP6600637B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/57525—
    • G01N33/5758—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2016552704A 2013-11-11 2014-11-11 膵臓がんを決定するための方法、アレイおよびそれらの使用 Expired - Fee Related JP6600637B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1319878.3 2013-11-11
GBGB1319878.3A GB201319878D0 (en) 2013-11-11 2013-11-11 Method, Array and use thereof
PCT/GB2014/053340 WO2015067969A2 (en) 2013-11-11 2014-11-11 Method, array and use thereof

Publications (3)

Publication Number Publication Date
JP2016537652A JP2016537652A (ja) 2016-12-01
JP2016537652A5 JP2016537652A5 (enExample) 2017-12-07
JP6600637B2 true JP6600637B2 (ja) 2019-10-30

Family

ID=49818441

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016552704A Expired - Fee Related JP6600637B2 (ja) 2013-11-11 2014-11-11 膵臓がんを決定するための方法、アレイおよびそれらの使用

Country Status (12)

Country Link
US (3) US20160252513A1 (enExample)
EP (1) EP3069143B1 (enExample)
JP (1) JP6600637B2 (enExample)
KR (1) KR102240473B1 (enExample)
CN (1) CN105917230B (enExample)
AU (1) AU2014345484B2 (enExample)
BR (1) BR112016010510A2 (enExample)
CA (1) CA2930211A1 (enExample)
ES (1) ES2704888T3 (enExample)
GB (1) GB201319878D0 (enExample)
MX (1) MX2016006125A (enExample)
WO (1) WO2015067969A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3851856A3 (en) 2007-03-27 2021-11-03 Immunovia AB Method, array and use thereof
GB201014837D0 (en) 2010-09-07 2010-10-20 Immunovia Ab Biomarker signatures and uses thereof
GB201103726D0 (en) 2011-03-04 2011-04-20 Immunovia Ab Method, array and use thereof
CN105021825B (zh) * 2015-07-09 2016-08-17 陈勇 一种检测胰腺癌相关多肽dap44的elisa试剂盒
GB201516801D0 (en) 2015-09-22 2015-11-04 Immunovia Ab Method, array and use thereof
GB201608192D0 (en) * 2016-05-10 2016-06-22 Immunovia Ab Method, array and use thereof
GB201609950D0 (en) * 2016-06-07 2016-07-20 Immunovia Ab Biomarkers signatures and uses thereof
GB201609951D0 (en) * 2016-06-07 2016-07-20 Immunovia Ab Biomarkers signatures and uses thereof
EP4053557A1 (en) * 2016-11-24 2022-09-07 Huvet Bio, Inc. Il-29 as a marker for a pancreatic disease
GB201701572D0 (en) * 2017-01-31 2017-03-15 Immunovia Ab Methods, arrays and uses thereof
KR102536314B1 (ko) * 2018-05-23 2023-05-25 주식회사 휴벳바이오 질환의 진단용 조성물
US11487739B2 (en) 2019-02-19 2022-11-01 Nasdaq, Inc. System and methods for data model detection and surveillance
CA3138991A1 (en) * 2019-05-02 2020-11-05 Ligandal, Inc. Methods and compositions for diagnostically-responsive ligand-targeted delivery of therapeutic agents
US20220326243A1 (en) * 2019-05-21 2022-10-13 Acurasysbio Co., Ltd. Composition for cancer diagnosis
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
KR102226826B1 (ko) * 2020-08-06 2021-03-11 주식회사 휴벳바이오 버피 코트 시료에 사용하기 위한 췌장암 진단용 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0039578B1 (en) 1980-05-02 1985-04-10 Edward P. Davis Leg aid device
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5856090A (en) 1994-09-09 1999-01-05 The Scripps Research Institute DNA-methylase linking reaction
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
US6727066B2 (en) * 2000-07-28 2004-04-27 Incyte Corporation Genes expressed in treated human C3A liver cell cultures
AU2003230838A1 (en) * 2002-04-05 2003-10-27 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Methods of diagnosing potential for metastasis or developing hepatocellular carcinoma and of identifying therapeutic targets
CN1703524B (zh) * 2002-09-30 2010-04-07 肿瘤疗法科学股份有限公司 与人胰腺癌相关的基因和多肽
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US7217807B2 (en) * 2002-11-26 2007-05-15 Rosetta Genomics Ltd Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
AU2004255216B2 (en) * 2003-07-01 2010-08-19 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
CN102344493B (zh) * 2004-05-28 2014-09-03 艾更斯司股份有限公司 结合于psca蛋白的用于癌症诊断的抗体
US8383357B2 (en) * 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
EP1871911A2 (en) * 2005-04-07 2008-01-02 Chiron Corporation Cancer-related genes (prlr)
JP2007051880A (ja) * 2005-08-15 2007-03-01 Tokyo Univ Of Science 膵臓癌の検出方法、膵臓癌の診断キット
DK1974058T3 (da) * 2006-01-11 2014-09-01 Genomic Health Inc Genekspressionsmarkører til prognosticering af kolorektal cancer
EP3851856A3 (en) * 2007-03-27 2021-11-03 Immunovia AB Method, array and use thereof
SG182976A1 (en) * 2007-06-29 2012-08-30 Ahngook Pharmaceutical Co Ltd Predictive markers for ovarian cancer
WO2009111067A2 (en) * 2008-03-07 2009-09-11 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal -like tumor cells or their formation
GB0815846D0 (en) * 2008-09-01 2008-10-08 Immunovia Ab diagnosis, prognosis and imaging of disease
CN113189342B (zh) * 2009-03-12 2024-12-03 癌症预防和治疗有限公司 鉴定、评估、预防以及治疗肺疾病的方法及试剂盒
WO2011039289A1 (de) * 2009-09-29 2011-04-07 Protagen Ag Markersequenzen für pankreaskrebserkrankungen, pankreaskarzinom und deren verwendung
MY185582A (en) * 2010-01-07 2021-05-24 Malaysian Palm Oil Board Anti-obesity and anti-dyslipidemic effects of oil palm phenolics in preventing atheroslerosis and cardiovascular disease
CN102279264A (zh) * 2010-06-09 2011-12-14 李彬 48种恶性肿瘤标志物抗体芯片的制备方法
US20120040858A1 (en) * 2010-08-13 2012-02-16 Morehouse School Of Medicine Biomarkers for stroke
GB201103726D0 (en) * 2011-03-04 2011-04-20 Immunovia Ab Method, array and use thereof
WO2012139628A1 (en) * 2011-04-11 2012-10-18 Lykera Biomed Sa Coding polypurine hairpins for the treatment of cancer

Also Published As

Publication number Publication date
KR20160085327A (ko) 2016-07-15
AU2014345484A1 (en) 2016-06-30
US20190128891A1 (en) 2019-05-02
AU2014345484B2 (en) 2020-08-27
EP3069143B1 (en) 2018-10-10
CN105917230B (zh) 2020-06-16
ES2704888T3 (es) 2019-03-20
CN105917230A (zh) 2016-08-31
US20160252513A1 (en) 2016-09-01
JP2016537652A (ja) 2016-12-01
MX2016006125A (es) 2016-08-12
CA2930211A1 (en) 2015-05-14
GB201319878D0 (en) 2013-12-25
US20220214344A1 (en) 2022-07-07
BR112016010510A2 (pt) 2017-12-05
WO2015067969A2 (en) 2015-05-14
KR102240473B1 (ko) 2021-04-15
WO2015067969A3 (en) 2015-08-06
EP3069143A2 (en) 2016-09-21

Similar Documents

Publication Publication Date Title
US20220214344A1 (en) Method, array and use thereof
US20200088742A1 (en) Method, array and use for determining the presence of pancreatic cancer
JP6465902B2 (ja) 腺癌の検出のための蛋白質シグネチャー／マーカー
JP6104796B2 (ja) 方法、アレイ、およびこれらの使用
CA2706786A1 (en) Diagnostic methods and arrays for use in the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190318

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190820

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191007

R150 Certificate of patent or registration of utility model

Ref document number: 6600637

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees